What is the significance of a parathyroid hormone (PTH) level of 268 pg/mL and what evaluation and treatment steps should be taken?

Evaluation and Management of PTH 268 pg/mL

A PTH level of 268 pg/mL is significantly elevated and requires immediate evaluation of serum calcium, phosphate, vitamin D status, and renal function to differentiate between primary hyperparathyroidism, secondary hyperparathyroidism, or normocalcemic primary hyperparathyroidism—each requiring distinct management pathways. 1

Initial Diagnostic Workup

Measure the following laboratory values immediately:

• Serum calcium (total and ionized) to determine if hypercalcemia is present 2, 3
• Serum phosphate to assess for hypophosphatemia (suggests primary hyperparathyroidism) or hyperphosphatemia (suggests secondary hyperparathyroidism) 1
• 25-hydroxyvitamin D level to exclude vitamin D deficiency as a cause of secondary hyperparathyroidism 4, 5, 6
• Estimated glomerular filtration rate (eGFR) to assess for chronic kidney disease 5, 3
• 24-hour urinary calcium excretion to evaluate for hypercalciuria 2, 3, 7

Important caveat: PTH assay results vary significantly between laboratories due to differences in antibody recognition of PTH fragments and lack of standardization, so the absolute value must be interpreted in the context of your laboratory's reference range (typically 10-65 pg/mL). 1

Interpretation Based on Calcium Status

If Hypercalcemic (Calcium >10.5 mg/dL or >2.62 mmol/L)

This indicates primary hyperparathyroidism (PHPT). 2, 3

Proceed with surgical evaluation if ANY of the following criteria are present:

• Serum calcium >10 mg/L (0.25 mmol/L) above the upper limit of normal 2, 3
• Bone mineral density T-score ≤-2.5 SD at any site 2, 3
• Previous fragility fracture or vertebral fracture on imaging 2, 3
• Kidney stones, nephrocalcinosis, or history of renal colic 2, 3
• eGFR <60 mL/min/1.73 m² 2, 3
• 24-hour urinary calcium >250 mg/day (6.25 mmol/day) in women or >300 mg/day (7.5 mmol/day) in men 2, 3
• Age <50 years (consider up to age 70 based on life expectancy) 3

Parathyroidectomy is the definitive treatment and is more cost-effective than observation or pharmacological therapy, even in asymptomatic patients. 3, 7 Surgery is associated with lower mortality and fewer cardiac complications compared to medical management alone. 8

If surgery is indicated, obtain preoperative imaging:

• Parathyroid ultrasound combined with either 99mTc-sestamibi scintigraphy (preferably with 123I subtraction) or 18F-choline PET-CT 2

If surgery is contraindicated or refused:

• Consider calcimimetics (cinacalcet) to lower PTH and calcium 5, 3
• Consider bisphosphonates for bone protection 3

If Normocalcemic (Calcium 8.5-10.5 mg/dL or 2.12-2.62 mmol/L)

This suggests normocalcemic primary hyperparathyroidism (NPHPT) if secondary causes are excluded. 9

Before diagnosing NPHPT, systematically exclude secondary hyperparathyroidism:

1. Check 25-hydroxyvitamin D: If <30 ng/mL (<75 nmol/L), supplement with cholecalciferol or ergocalciferol until levels exceed 20 ng/mL (50 nmol/L) and recheck PTH in 3-6 months 4, 5, 6
2. Assess dietary calcium intake: Low urinary calcium excretion suggests calcium deprivation requiring supplementation 4
3. Evaluate for malabsorption syndromes (post-bariatric surgery, celiac disease, inflammatory bowel disease) 1
4. Confirm eGFR >60 mL/min/1.73 m² to exclude early CKD 5

If secondary causes are excluded and PTH remains elevated on at least two occasions over 3-6 months:

• Evaluate for target organ damage (bone densitometry, renal imaging) 9
• If kidney stones, osteoporosis (T-score ≤-2.5), or fractures are present, surgical referral is appropriate 2, 3
• If asymptomatic, monitor calcium, PTH, and bone density annually 9

If Hypocalcemic or in the Setting of CKD

This indicates secondary hyperparathyroidism (SHPT). 1, 5

For CKD Stage 3a-5 (eGFR <60 mL/min/1.73 m²):

The 2017 KDIGO guidelines recommend treating when PTH is progressively rising or persistently above the upper normal limit after addressing modifiable factors. 5

Step 1: Correct modifiable factors first:

• Treat hyperphosphatemia with dietary phosphate restriction and phosphate binders 5
• Correct vitamin D deficiency (target 25-OH vitamin D >20 ng/mL) with cholecalciferol 4, 5, 6
• Ensure adequate calcium intake (meet age-related recommended dietary allowance) 4

Step 2: If PTH remains elevated despite correction:

• For CKD G3a-G5 not on dialysis: Reserve calcitriol or vitamin D analogs for severe and progressive hyperparathyroidism (CKD G4-G5) 5
• For CKD G5D (dialysis patients): Target intact PTH of 150-300 pg/mL (2-9 times upper normal limit) 10, 5, 6, 11

For dialysis patients with PTH 268 pg/mL (within target range):

• Continue current therapy and monitor PTH every 3 months 6
• Measure serum calcium and phosphorus at least every 2 weeks initially, then monthly 6
• Use calcimimetics, calcitriol, vitamin D analogs, or combination therapy to maintain PTH in target range 5

Parathyroidectomy should be considered for dialysis patients with:

• Severe, refractory SHPT despite maximal medical therapy 8, 12
• Persistent hypercalcemia or hyperphosphatemia limiting medical management 12
• Calciphylaxis or severe bone pain 12

Recent evidence shows parathyroidectomy in dialysis patients is associated with lower mortality (HR 0.68,95% CI 0.58-0.80) and fewer cardiac events compared to calcimimetics alone, even with moderately elevated PTH. 8

Common Pitfalls to Avoid

• Do not assume all elevated PTH is primary hyperparathyroidism—vitamin D deficiency is extremely common and must be excluded first 4, 5, 6
• Do not compare PTH values across different laboratories or assays—lack of standardization means a PTH of 268 pg/mL may represent different biological activity depending on the assay used 1
• Do not delay vitamin D supplementation while waiting for PTH to normalize—correct vitamin D deficiency first, then reassess PTH after 3-6 months 4, 5
• In CKD patients, do not target normal PTH levels—mild elevation (2-9 times upper normal) is appropriate to prevent adynamic bone disease 10, 5, 11
• Do not use cinacalcet in patients with X-linked hypophosphatemia—it can cause severe hypocalcemia and QT prolongation 4, 6